INT72676

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 34
Total Number 34
Disease Relevance 34.15
Pain Relevance 1.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (APOA1) small molecule metabolic process (APOA1) extracellular region (APOA1)
plasma membrane (APOA1) enzyme binding (APOA1) transmembrane transport (APOA1)
Anatomy Link Frequency
plasma 4
adipocyte 2
Body 2
erythrocyte 1
brush 1
APOA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bile 103 97.12 Very High Very High Very High
agonist 43 95.28 Very High Very High Very High
aspirin 29 92.48 High High
Inflammation 144 83.20 Quite High
Angina 31 68.48 Quite High
alcohol 28 52.52 Quite High
cINOD 10 52.24 Quite High
rheumatoid arthritis 9 51.52 Quite High
Sicca syndrome 6 44.64 Quite Low
Pain 11 43.72 Quite Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 2099 100.00 Very High Very High Very High
Atherosclerosis 210 99.64 Very High Very High Very High
Increased Venous Pressure Under Development 240 99.40 Very High Very High Very High
Stress 16 99.36 Very High Very High Very High
Obesity 281 99.22 Very High Very High Very High
Cardiovascular Disease 472 98.44 Very High Very High Very High
Systemic Sclerosis 321 98.36 Very High Very High Very High
Mental Disorders 4 98.36 Very High Very High Very High
Coronary Artery Disease 780 97.84 Very High Very High Very High
Familial Combined Hyperlipidemia 18 96.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Overexpression of ApoAI or infusion of ApoA-I in animal models increases HDL-C levels and decreases atherosclerosis.
Gene_expression (Overexpression) of ApoA-I associated with increased venous pressure under development and disorder of lipid metabolism
1) Confidence 0.75 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.07 Pain Relevance 0.08
The inhibition of growth is associated with a dose-dependent reduction in insulin-like growth factor II mRNA expression and with an increase in sucrase activity (a brush border enzyme) and apolipoprotein A-I mRNA expression, 2 specific markers of the differentiative status of this cell line.
Gene_expression (expression) of apolipoprotein A-I in brush associated with disorder of lipid metabolism
2) Confidence 0.65 Published 1997 Journal Int. J. Cancer Section Abstract Doc Link 9399670 Disease Relevance 0.74 Pain Relevance 0.32
Then, the following parameters were measured: 1) the concentrations of serum lipid including total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, Apolipoprotein AI (Apo AI), Apolipoprotein B (Apo B) and lipoprotein (a) [Lp (a)]; 2) leukocyte count, monocyte count, erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP); and 3) the concentrations of fibrinogen, fibrinogen degradation product (FDP) and homocysteine.
Gene_expression (concentrations) of Apo AI in erythrocyte associated with disorder of lipid metabolism
3) Confidence 0.65 Published 2006 Journal Journal of Korean Medical Science Section Body Doc Link PMC2733993 Disease Relevance 1.53 Pain Relevance 0.20
Another potential target for raising HDL-C levels is augmenting ApoA-I levels (an important protein in HDL-C).
Gene_expression (levels) of ApoA-I associated with disorder of lipid metabolism
4) Confidence 0.65 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.00 Pain Relevance 0.07
The two main ApoA-I peptides currently under investigation are the ApoA-IMilano complex and the D-4F peptide.
Gene_expression (complex) of ApoA-I
5) Confidence 0.65 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.04 Pain Relevance 0.09
Apolipoprotein AI (apoAI) and apolipoprotein B (apoB) were assayed using immunoturbidimetric methods, using reagents supplied by ABX Diagnostics.
Gene_expression (assayed) of apoAI associated with disorder of lipid metabolism
6) Confidence 0.65 Published 2008 Journal Atherosclerosis Section Body Doc Link PMC2292239 Disease Relevance 0.38 Pain Relevance 0
Apolipoprotein AI (apoAI) and apolipoprotein B (apoB) were assayed using immunoturbidimetric methods, using reagents supplied by ABX Diagnostics.
Gene_expression (assayed) of Apolipoprotein AI associated with disorder of lipid metabolism
7) Confidence 0.65 Published 2008 Journal Atherosclerosis Section Body Doc Link PMC2292239 Disease Relevance 0.39 Pain Relevance 0
The two main ApoA-I peptides currently under investigation are the ApoA-IMilano complex and the D-4F peptide.
Gene_expression (complex) of ApoA-I
8) Confidence 0.65 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.11 Pain Relevance 0.09
3.1 ApoB/ApoA1 ratio
Gene_expression (ratio) of ApoA1
9) Confidence 0.64 Published 2008 Journal BMC Med Inform Decis Mak Section Body Doc Link PMC2601038 Disease Relevance 1.39 Pain Relevance 0
2.3.1 ApoB/ApoA1 ratio
Gene_expression (ratio) of ApoA1
10) Confidence 0.64 Published 2008 Journal BMC Med Inform Decis Mak Section Body Doc Link PMC2601038 Disease Relevance 1.02 Pain Relevance 0.03
Their contribution is via promotion of atherogenesis, in which regard ApoA1 levels seem to take a leading role.
Gene_expression (levels) of ApoA1 associated with atherosclerosis
11) Confidence 0.55 Published 2006 Journal Osteoporos Int Section Body Doc Link PMC1820757 Disease Relevance 0.76 Pain Relevance 0
Patients with CVD had significantly higher concentrations of serum apoB, apoB/apoA-I ratio and Lp(a), and lower levels of apoA-I compared to patients without incident CVD.
Gene_expression (levels) of apoA-I associated with cardiovascular disease
12) Confidence 0.55 Published 2006 Journal Biomark Insights Section Abstract Doc Link PMC2716782 Disease Relevance 0.76 Pain Relevance 0
In our study, patients with prominent CVD had elevated serum apoB and Lp(a) levels and apoB/apoA-I ratio values, as well as lower serum levels of apoA-I compared to patients without prevalent CVD.
Gene_expression (levels) of apoA-I associated with cardiovascular disease
13) Confidence 0.55 Published 2006 Journal Biomark Insights Section Body Doc Link PMC2716782 Disease Relevance 0.86 Pain Relevance 0
Levels of apoA-I are strongly associated with those of HDL cholesterol.
Gene_expression (Levels) of apoA-I associated with disorder of lipid metabolism
14) Confidence 0.55 Published 2006 Journal Biomark Insights Section Body Doc Link PMC2716782 Disease Relevance 0.80 Pain Relevance 0.03
We show here that apoA-I strongly stimulates apoE secretion, suggesting that in pathological conditions, such as obesity, the combination of low HDL-c levels (carrying apoA-I) and oxidative stress contributes to a major reduction in adipocyte apoE secretion.
Gene_expression (carrying) of apoA-I in adipocyte associated with stress, obesity and disorder of lipid metabolism
15) Confidence 0.54 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.96 Pain Relevance 0.10
This suggests that the effect of the apoA-I is not directly linked to the activation of ABCA1, or at least, that in adipocyte, the activation of ABCA1 occurs through an undescribed signaling pathway.
Gene_expression (effect) of apoA-I in adipocyte
16) Confidence 0.54 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.34 Pain Relevance 0
Medium was removed and replaced with either medium alone or medium containing apoA-I (10 ?
Gene_expression (containing) of apoA-I
17) Confidence 0.54 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.40 Pain Relevance 0
Multivariate analysis showed significant differences in the mean TG levels across the Sac-1 genotype (P = 0.007), with mean LDL-cholesterol levels across the -75G>A genotypes (P = 0.043) and with ApoA1 levels across the S19W genotypes (P = 0.026).
Gene_expression (levels) of ApoA1
18) Confidence 0.53 Published 2008 Journal Lipids Health Dis Section Body Doc Link PMC2556320 Disease Relevance 0.54 Pain Relevance 0
ApoA: Apolipoprotein A; APOA1: Apolipoprotein A1 gene; APOA5: Apolipoprotein A5 gene; ApoB: Apolipoprotein B; APOC3: Apolipoprotein C3 gene; ASPs: Affected sibling pairs; BMI: Body mass index; CAD: Coronary Artery Disease; FCHL: Familial Combined Hyperlipidemia; HDL-c: High-Density Lipoprotein cholesterol; HTN: Hypertension; IBD: Identity By Descent; IBS: Identity By State.
Gene_expression (gene) of APOA1 in Body associated with inflammatory bowel disease, familial combined hyperlipidemia, coronary artery disease, hypertension, obesity and disorder of lipid metabolism
19) Confidence 0.53 Published 2008 Journal Lipids Health Dis Section Body Doc Link PMC2556320 Disease Relevance 2.02 Pain Relevance 0
ApoA: Apolipoprotein A; APOA1: Apolipoprotein A1 gene; APOA5: Apolipoprotein A5 gene; ApoB: Apolipoprotein B; APOC3: Apolipoprotein C3 gene; ASPs: Affected sibling pairs; BMI: Body mass index; CAD: Coronary Artery Disease; FCHL: Familial Combined Hyperlipidemia; HDL-c: High-Density Lipoprotein cholesterol; HTN: Hypertension; IBD: Identity By Descent; IBS: Identity By State.
Gene_expression (gene) of APOA1 in Body associated with inflammatory bowel disease, familial combined hyperlipidemia, coronary artery disease, hypertension, obesity and disorder of lipid metabolism
20) Confidence 0.53 Published 2008 Journal Lipids Health Dis Section Body Doc Link PMC2556320 Disease Relevance 1.91 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox